Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 8, 2014, Pages 1655-1666

  Xu, Dong ^a,b   Qu, Liujing ^a,b   Hu, Jia ^a,b   Li, Ge ^a,b   Lv, Ping ^a,b   Ma, Dalong ^a,b   Guo, Mingzhou ^c   Chen, Yingyu ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Epigenetic alteration; Gastric cancer; Transmembrane protein 106A

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DNA METHYLATION; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA METHYLATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84912526581     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12352     Document Type: Article

References (36)

1. Moon YW, Jeung HC, Rha SY, et al. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. Ann Surg Oncol. 2007; 14: 2730-7.
2. Kang GH, Lee HJ, Hwang KS, et al. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol. 2003; 163: 1551-6.
3. Kang GH, Lee S, Kim JS, et al. Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest. 2003; 83: 519-26.
4. Lee JH, Park SJ, Abraham SC, et al. Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene. 2004; 23: 4646-54.
5. Cruchaga C, Graff C, Chiang HH, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol. 2011; 68: 581-6.
6. Finch N, Carrasquillo M, Baker M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011; 76: 467-74.
7. Van Deerlin VM, Sleiman PMA, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010; 42: 234-9.
8. Van Der Zee J, Van Langenhove T, Kleinberger G, et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain. 2011; 134: 808-15.
9. van der Zee J, Van Broeckhoven C. TMEM106B a novel risk factor for frontotemporal lobar degeneration. J Mol Neurosci. 2011; 45: 516-21.
10. Wood HB. TMEM106B is a susceptibility locus for Ftld. Nat Rev Neurol. 2010; 6: 184.
11. Rollinson S, Mead S, Snowden J, et al. Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. Neurobiol Aging. 2011; 32: e751-7.
12. Vass R, Ashbridge E, Geser F, et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011; 121: 373-80.
13. Rutherford NJ, Carrasquillo MM, Li M, et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology. 2012; 79: 717-8.
14. Lang CM, Fellerer K, Schwenk BM, et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for fronto temporal lobar degeneration. J Biol Chemn. 2012; 287: 19355-65.
15. Brady OA, Zheng Y, Murphy K, et al. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet. 2013; 22: 685-95.
16. Assassi S, Reveille JD, Arnett FC, et al. Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of Toll-like receptor 4 and 5. J Rheumatol. 2011; 38: 87-98.
17. Genini S, Nguyen T, Malek M, et al. Radiation hybrid mapping of 18 positional and physiological candidate genes for arthrogryposis multiplex congenita on porcine chromosome 5. Anim Gene. 2006; 37: 239-44.
18. Yu W, Ramakrishnan R, Wang Y, et al. Cyclin T1-dependent genes in activated CD4 + T and macrophage cell lines appear enriched in HIV-1 co-factors. PLoS ONE. 2008; 3: e3146.
19. Wang L, Gao X, Gao P, et al. Cell-based screening and validation of human novel genes associated with cell viability. J Biomol Screen. 2006; 11: 369-76.
20. Chen L, Wang Y, Ma D, et al. Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis. 2006; 11: 101-11.
21. Jia Y, Yang Y, Liu S, et al. SOX17 antagonizes WNT/b-catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 2010; 5: 743-9.
22. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996; 93: 9821-6.
23. Chang Y, Li Y, Hu J, et al. Adenovirus vector- mediated expression of TMEM166 inhibits human cancer cell growth by autophagy and apoptosis in vitro and in vivo. Cancer Lett. 2013; 328: 126-34.
24. Sonnhammer E, Von Heijne G, Krogh A. A hidden Markov model for predicting transmembrane helices in protein sequences. Proc Int Conf Intell Syst Mol Biol. 1998; 6: 175-82.
25. Guo Y, Srinivasula SM, Druilhe A, et al. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chemn. 2002; 277: 13430-7.
26. Bouchier-Hayes L, Green D. Caspase-2: the orphan caspase. Cell Death Differ. 2012; 19: 51-7.
27. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell. 2003; 11: 529-41.
28. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415-28.
29. House MG, Guo M, Efron DT, et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg. 2003; 7: 1004-14.
30. Issa JPJ. Methylation and prognosis. Clin Cancer Res. 2003; 9: 2879-81.
31. van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003; 9: 2898-903.
32. Umetani N, Takeuchi H, Fujimoto A, et al. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res. 2004; 10: 7475-83.
33. Guo M, Ren J, House MG, et al. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006; 12: 4515-22.
34. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008; 358: 1118-28.
35. Park YJ, Claus R, Weichenhan D, et al. Genome-wide epigenetic modifications in cancer. Prog Drug Res. 2011; 67: 25-49.
36. Blum HE. Gastrointestinal and liver diseases: genetic and epigenetic markers. Gut. 2011; 60: 1630-4.